The heart of drug discovery research is screening technologies. Because screening is so important in identifying and validating targets, the quality of the screening technique used can be a decisive factor in whether or not a new drug makes it to the clinic. To discover chemical compounds that can be manufactured and marketed, a variety of methods are used. Over the last 40 years, the complexity of medication development has skyrocketed. New drugs are developed through drug discovery. Drugs were formerly discovered mostly through discovering active components in traditional medications or by pure accident. Drug discovery nowadays entails hit screening, medicinal chemistry, and hit optimization to limit potential drug side effects (increasing affinity and selectivity). This stage of the medication development process also improves efficacy or potency, metabolic stability (half-life), and oral bioavailability.
In Vitro Models for Drug Screening
John K Maesaka
NYU Langone Hospital Long Island, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Saad Tayyab
UCSI University, Malaysia
Vladlen Slepak
University of Miami, United States
Andreas M Papas
East Tennessee State University, United States
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Alessandro Gallo
Springer Healthcare, Italy
Gurpreet Singh
IQVIA, United Kingdom
Maria Cristina Gamberini
University of Modena e Reggio Emilia, ItalySubmit your abstract Today
Title : Liver biopsy handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The children's hospital of eastern Ontario grossing protocol
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Haptoglobin-Related Protein Without Signal Peptide as biomarker of renal salt wasting (HPRWSP) in hyponatremia, hyponatremia-related diseases and as new syndrome in alzheimer’s disease
John K Maesaka, NYU Langone Hospital Long Island, United States
Title : Enabling knowledge-driven integration and interoperability in intelligent and ethical transformed health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami, United States
Title : Revolutionizing healthcare and pharma: Artificial intelligence-powered scientific communications and medical writing
Alessandro Gallo, Springer Healthcare, Italy
Title : Understanding drug transport in plasma: the role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up via biodesign-driven biotech and upgraded biomarketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Cell viability assays under radiofrequency application modulated by nanomaterials
Paulo C De Morais, Catholic University of Brasilia, Brazil
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Biosimilars - The current progress
Miroslav Radenkovic, University of Belgrade, Serbia